Profile data is unavailable for this security.
About the company
Cosmo Pharmaceuticals N.V. is a specialty pharmaceutical company. The Company develops therapies for gastrointestinal disorders. The Company's clinical development pipeline specifically addresses treatments for inflammatory bowel diseases, colorectal cancer diagnosis and colonoscopy. It has developed a medical device for polyp excision and is developing a product for the detection of colon cancer. Its pipeline includes Lialda/Mezavant/Mesavancol, which is indicated for mild to moderate ulcerative colitis; Uceris/Cortiment, which is indicated for mild to moderate ulcerative colitis; Zacol NMX, which is indicated for intestinal disorders; Rifamycin SV MMX, which is indicated for Travelers' Diarrhea and uncomplicated diverticulitis, among others; CB-17-01, which is indicated for chromoendoscopy for colorectal cancer prevention in surveillance patients; CB-17-04, which is a sub mucosal injectable composition, and CB-01-12, which is an antibody anti-tumor necrosis factor (TNF) alpha drug.
- Revenue in CHF (TTM)65.86m
- Net income in CHF-11.02m
- Incorporated--
- Employees276.00
- LocationCosmo Pharmaceuticals NVRiverside II, Sir John Rogerson's QuayDUBLIN IrelandIRL
- Phone+353 18170370
- Websitehttp://www.cosmopharma.com/
Mergers & acquisitions
| Acquired company | COPN:SWX since announced | Transaction value |
|---|---|---|
| Cassiopea SpA | -29.18% | 228.73m |
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| RELIEF THERAPEUTICS Holding SA | 0.00 | -30.76m | 291.04m | 24.00 | -- | 1.80 | -- | -- | -0.0104 | -0.0104 | 0.00 | 0.0367 | 0.00 | -- | -- | -- | -28.70 | -22.60 | -32.74 | -24.44 | -- | -- | -- | -6,111.21 | 1.78 | -69.18 | 0.0693 | -- | -- | -- | -4.93 | -- | -- | -- |
| Basilea Pharmaceutica AG | 112.50m | -44.55m | 546.47m | 220.00 | -- | -- | -- | 4.86 | -4.24 | -4.24 | 10.53 | -6.68 | 0.5304 | 1.44 | 19.13 | 511,359.10 | -21.00 | -9.30 | -25.55 | -12.18 | 78.23 | 86.20 | -39.60 | -24.76 | 5.28 | -4.33 | 1.53 | -- | -5.02 | 19.29 | 34.34 | -- | 11.54 | -- |
| Molecular Partners AG | -100.00bn | -100.00bn | 810.27m | 158.00 | -- | 6.51 | -- | -- | -- | -- | -- | 3.85 | -- | -- | -- | -- | -- | -22.74 | -- | -27.52 | -- | 96.59 | -- | -216.66 | -- | -- | 0.0484 | -- | -54.16 | -20.33 | -72.96 | -- | 1.21 | -- |
| Cosmo Pharmaceuticals NV | 65.86m | -11.02m | 986.95m | 276.00 | -- | 2.09 | -- | 14.99 | -0.7645 | -0.7645 | 4.57 | 26.85 | 0.1095 | 3.42 | 3.67 | 248,521.60 | -1.83 | -2.38 | -1.89 | -2.47 | 55.00 | 64.02 | -16.74 | -19.62 | 14.07 | 0.4211 | 0.3118 | -- | -2.47 | 0.1126 | 67.64 | -- | 26.09 | -- |
| Dottikon ES Holding AG | 228.95m | 55.10m | 3.05bn | 658.00 | 51.58 | 4.41 | 40.42 | 13.33 | 4.23 | 4.23 | 17.40 | 49.38 | 0.3429 | 0.4184 | 5.79 | 358,287.90 | 8.25 | 6.44 | 9.35 | 7.21 | 80.22 | 82.32 | 24.07 | 17.59 | 3.38 | -- | 0.00 | -- | 25.25 | 12.51 | 57.77 | 29.67 | 31.33 | -- |
| Siegfried Holding AG | 923.87m | 44.59m | 3.15bn | 3.43k | 66.42 | 3.82 | 22.82 | 3.41 | 10.78 | 10.78 | 221.20 | 187.61 | 0.6699 | 2.10 | 4.21 | 364,878.80 | 5.04 | 4.36 | 6.00 | 5.21 | 21.25 | 19.12 | 7.52 | 6.07 | 1.21 | 91.02 | 0.2469 | 28.01 | 1.39 | 11.95 | -25.12 | -2.40 | -6.16 | -- |
| Idorsia Ltd | 36.19m | -519.91m | 3.68bn | 636.00 | -- | 15.34 | -- | 101.79 | -3.17 | -3.17 | 0.2206 | 1.36 | 0.0265 | -- | 7.21 | -- | -38.13 | -- | -42.12 | -- | -- | -- | -1,436.46 | -- | -- | -147.58 | 0.8395 | -- | 201.26 | -- | 9.89 | -- | -- | -- |
| BACHEM HOLDING AG | 464.00m | 98.35m | 4.06bn | 1.58k | 74.55 | 15.04 | 32.46 | 8.75 | 7.03 | 7.03 | 33.16 | 34.85 | 0.6477 | 1.24 | 6.30 | 314,573.60 | 13.73 | 9.09 | 18.53 | 11.65 | 32.95 | 31.05 | 21.20 | 17.50 | 0.4335 | 30.10 | 0.2301 | 74.88 | 28.14 | 14.02 | 44.12 | 19.65 | 25.00 | 7.63 |
| Holder | Shares | % Held |
|---|---|---|
| UBS Asset Management Switzerland AGas of 12 Jan 2022 | 524.55k | 2.99% |
| AMG Fondsverwaltung AGas of 30 Jun 2021 | 314.77k | 1.79% |
| The Vanguard Group, Inc.as of 06 Jan 2022 | 259.46k | 1.48% |
| Baillie Gifford & Co.as of 30 Nov 2021 | 220.15k | 1.26% |
| Norges Bank Investment Managementas of 31 Dec 2020 | 136.82k | 0.78% |
| Credit Suisse Asset Management (Schweiz) AGas of 31 Dec 2021 | 123.00k | 0.70% |
| BlackRock Fund Advisorsas of 06 Jan 2022 | 116.22k | 0.66% |
| Sp-Fund Management Co. Ltd.as of 30 Nov 2021 | 93.60k | 0.53% |
| Z�rcher Kantonalbank (Investment Management)as of 31 Dec 2020 | 57.54k | 0.33% |
| Bessemer Investment Management LLCas of 29 Oct 2021 | 52.83k | 0.30% |
